首页> 外文期刊>Neuro-Oncology >Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG
【24h】

Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG

机译:更好吗?扩展的替莫唑胺辅助治疗对新诊断的胶质母细胞瘤的影响:EORTC和NRG肿瘤学/ RTOG的二级分析

获取原文
获取原文并翻译 | 示例
           

摘要

Background: Radiation with concurrent and adjuvant (6 cycles) temozolomide (TMZ) is the established standard of postsurgical care for newly diagnosed glioblastoma (GBM). This regimen has been adopted with variations, including extending TMZ beyond 6 cycles. The optimal duration of maintenance therapy remains controversial.
机译:背景:替莫唑胺(TMZ)同时和辅助(6个周期)放射是新诊断的胶质母细胞瘤(GBM)的术后护理的既定标准。该方案已被采用,包括将TMZ扩展到6个周期以上。维持治疗的最佳持续时间仍存在争议。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号